CD44 and triple-negative breast carcinoma: The experimental design of GNS/siHSP72/HA, which specifically introduces siHSP72 into CD44-positive cells, particularly sensitizes triple-negative breast cancer cells by downregulating HSP72 overexpression in CD44-positive cells and improves the effect of PTT on TNBC with lowest damage to healthy cells.